Tamoxifen's clinical applications: Old and new

Archives of Family Medicine

Volumn 9, Issue 9, 2000, Pages 906-912

  Buzdar, A U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; MELPHALAN; TAMOXIFEN CITRATE;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; META ANALYSIS; PATIENT COUNSELING; REVIEW; RISK FACTOR; SURVIVAL RATE; THROMBOEMBOLISM;

EID: 0033791553     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.9.9.906     Document Type: Review

References (30)

1. The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
3. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
4. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
5. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
6. Tamoxifen for early breast cancer: An overview of the randomized trials
7. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
8. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group
9. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer
10. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA1
11. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial
12. Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: A long-term follow-up
13. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death
14. The use of endocrine therapy
15. Diagnosis and therapy of breast cancer: The use of endocrine therapy
16. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at eight years
17. Highlights of the NSABP breast cancer prevention trial
18. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial
19. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer
20. Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up: Cancer Research Campaign Breast Cancer Trials Group
21. Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer
22. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
23. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
24. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies
25. Polychemotherapy for early breast cancer: An overview of the randomised trials
26. Epidemiology and biostatistics program of the National Cancer Institute
27. Prevention of breast cancer with tamoxifen: Preliminary findings from the italian randomised trial among hysterectomised women
28. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
29. Update of the NCCN guidelines for treatment of breast cancer
30. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer